Circio issues invitation to R&D and corporate update webcast on 24 November 2025
17 november, 14:00
- CTO Dr. Thomas B Hansen will present a summary of novel circVec in vitro and in vivo results and ongoing R&D activities and plans
- CEO Dr. Erik D Wiklund will provide a corporate update
Oslo, Norway, 17 November 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, issues an invitation to a live webcast at 10:00am CET on Monday 24 November 2025.
In the webcast, CTO Dr. Thomas B Hansen will present Circio´s latest in vitro and in vivo results on the circVec circular RNA expression platform. Recent findings include design and testing of novel circVec constructs and extended in vivo screening and validation of circVec for AAV gene therapy.
CEO Dr. Erik D Wiklund will provide a general corporate and strategy update.
Presenters:
CEO Dr. Erik Digman Wiklund
CTO Dr. Thomas Birkballe Hansen
Time: 10:00 CET on 24 November 2025
Click here to access Teams webcast
Meeting ID: 366 918 860 415 63
Passcode: Kn2Pq9pM
Questions can be submitted in advance by email to Erik D Wiklund: erik.wiklund@circio.com or directly in the live webcast
A recording of the webcast will be made available on the Circio webpage
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com
About Circio
Building circular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.
Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.
Ämnen i artikeln
Circio issues invitation to R&D and corporate update webcast on 24 November 2025
17 november, 14:00
- CTO Dr. Thomas B Hansen will present a summary of novel circVec in vitro and in vivo results and ongoing R&D activities and plans
- CEO Dr. Erik D Wiklund will provide a corporate update
Oslo, Norway, 17 November 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, issues an invitation to a live webcast at 10:00am CET on Monday 24 November 2025.
In the webcast, CTO Dr. Thomas B Hansen will present Circio´s latest in vitro and in vivo results on the circVec circular RNA expression platform. Recent findings include design and testing of novel circVec constructs and extended in vivo screening and validation of circVec for AAV gene therapy.
CEO Dr. Erik D Wiklund will provide a general corporate and strategy update.
Presenters:
CEO Dr. Erik Digman Wiklund
CTO Dr. Thomas Birkballe Hansen
Time: 10:00 CET on 24 November 2025
Click here to access Teams webcast
Meeting ID: 366 918 860 415 63
Passcode: Kn2Pq9pM
Questions can be submitted in advance by email to Erik D Wiklund: erik.wiklund@circio.com or directly in the live webcast
A recording of the webcast will be made available on the Circio webpage
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com
About Circio
Building circular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.
Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.
Ämnen i artikeln
Analyser
Aktieråd
SBB
Inflationen
Analyser
Aktieråd
SBB
Inflationen
Marknadsöversikt
1 DAG %
Senast
1 mån
